BOSTON, March 24, 2011 /PRNewswire/ — Solos Endoscopy, Inc.
(Pink Sheets:
SNDY) is pleased to announce that the Company has strengthened
its current line of Laparoscopic surgical instruments in order to
better align its product offerings with current global endoscopy
market trends.
Solos has focused its R & D efforts into the design and
development of new modifications to its endoscopic instrument lines
to accommodate the continual advances in Laparoscopic surgical
procedures including bile duct reconstruction, laparoscopic
adrenalectomy and distal pancreatectomy, amongst a host of other
operations and diagnostic applications. The significant advances
over the past several years have led to a number of advantages to
the patient with laparoscopic surgery versus an open procedure
(laparotomy). These advantages include reduced pain due to smaller
incisions and hemorrhaging, and shorter recovery time.
According to salisonline.org, the market for endoscopy devices
is projected to grow at a Compound Annual Growth Rate (CAGR) of
5.5% from 2009-2015, with growth driven by innovations in endoscopy
technology and expansion of indications suitable for endoscopic
surgery. The article went on to acknowledge that laparoscopy is the
largest segment, contributing 27% to the global endoscopy market
and is projected to grow at a CAGR of 8% until 2015, becoming the
largest growth opportunity in endoscopy.
“We are highly enthusiastic regarding the prospects for Solos’
next generation portfolio of endoscopic and laparoscopic
instrumentation, which are expected to provide the opportunity to
regain momentum and expand our revenue growth,” stated Bob
Segersten, President of Solos Endoscopy, Inc.
The Company expects to post its full unaudited financial results
for the fiscal year ended December 31, 2010 on the OTC Markets
Group website within in the next week.
Ab
‘/>”/>
